Yamamoto Hironori, Yahagi Naohisa, Oyama Tsuneo, Gotoda Takuji, Doi Toshihiko, Hirasaki Shoji, Shimoda Tadakazu, Sugano Kentaro, Tajiri Hisao, Takekoshi Takao, Saito Daizo
Current affiliations: Department of Internal Medicine, Division of Gastroenterology, Jichi Medical School, Tochigi, Japan.
Gastrointest Endosc. 2008 May;67(6):830-9. doi: 10.1016/j.gie.2007.07.039. Epub 2007 Dec 26.
Sodium hyaluronate (SH) solution has been used for submucosal injection in endoscopic resection to create a long-lasting submucosal fluid "cushion."
Our purpose was to assess the usefulness and safety of 0.4% SH solution in endoscopic resection.
A prospective multicenter randomized controlled trial.
Six referral hospitals in Japan.
One hundred forty patients with 5- to 20-mm gastric intramucosal neoplastic lesions.
Patients were randomized into 0.4% SH and control groups. Endoscopic resection was performed with 0.4% SH or normal saline solution for submucosal injection.
The usefulness of 0.4% SH solution was assessed by en bloc complete resection and the formation and maintenance of mucosal lesion-lifting during endoscopic resection.
(1) steepness of mucosal lesion lifting, (2) complications, (3) time required for mucosal resection, (4) volume of submucosal injection solution, and (5) ease of mucosal resection. Safety was assessed by analyzing adverse events during the study period.
The usefulness rate was significantly higher for the 0.4% SH group (88.4%, 61/69) than for the control group (58.6%, 41/70). As secondary outcome measures, significant intergroup differences (P < .001) were noted for (1) steepness of mucosal lesion lifting, (2) volume of submucosal injection solution, and (3) ease of mucosal resection. No serious adverse events were encountered in either group.
Lack of blinding. Safety was not a powered outcome measure.
Using 0.4% SH as a submucosal injection solution in endoscopic resection enabled the formation and maintenance of sufficient mucosal lesion lifting for gastric intramucosal lesions, reducing the need for additional injections and simplifying mucosal resection. Use of 0.4% SH thus simplifies the complicated procedures involved in endoscopic resection.
透明质酸钠(SH)溶液已用于内镜切除术中的黏膜下注射,以形成持久的黏膜下液体“垫”。
我们的目的是评估0.4% SH溶液在内镜切除术中的有效性和安全性。
一项前瞻性多中心随机对照试验。
日本的六家转诊医院。
140例患有5至20毫米胃黏膜内肿瘤性病变的患者。
患者被随机分为0.4% SH组和对照组。内镜切除术中使用0.4% SH或生理盐水进行黏膜下注射。
通过整块完整切除以及内镜切除术中黏膜病变抬举的形成和维持来评估0.4% SH溶液的有效性。
(1)黏膜病变抬举的陡峭程度,(2)并发症,(3)黏膜切除所需时间,(4)黏膜下注射溶液的体积,(5)黏膜切除的难易程度。通过分析研究期间的不良事件来评估安全性。
0.4% SH组的有效性率(88.4%,61/69)显著高于对照组(58.6%,41/70)。作为次要观察指标,在(1)黏膜病变抬举的陡峭程度、(2)黏膜下注射溶液的体积和(3)黏膜切除的难易程度方面,组间存在显著差异(P <.001)。两组均未遇到严重不良事件。
缺乏盲法。安全性不是一项有足够效力的观察指标。
在内镜切除术中使用0.4% SH作为黏膜下注射溶液能够为胃黏膜内病变形成并维持足够的黏膜病变抬举,减少额外注射的需要并简化黏膜切除。因此,使用0.4% SH简化了内镜切除术中涉及的复杂操作。